U.S., Nov. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07225998) titled 'Oral N-acetylglucosamine in Crohn's Disease' on Oct. 29.
Brief Summary: This study is a clinical trial of oral N-acetylglucosamine (GlcNAc) in patients with Crohn's disease (CD). This study includes two study groups divided by gene variation in a transporter protein that regulates manganese levels. This genetic variant increases the risk of Crohn's disease (especially involving the ileum) and is carried by approximately 10% of individuals with Crohn's disease. This genetic variant lowers manganese levels, and manganese is important in a cellular process called glycosylation, therefore, glycosylation is changed. Glycosylation in the ...